Prognostic Biomarkers in Patients With Urothelial Carcinoma

Hellenic Cooperative Oncology Group

Status: Completed

Conditions: Bladder Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT04872036

Biomarkers_Urothelial

Details and patient eligibility

About

Bladder cancer (BC) is a heterogeneous malignancy with dismal outcome.Despite treatment, the 5-year overall survival rates for MIBC are <50%, with many patients unresponsive or inapt, necessitating biomarkers to select those most likely to respond or fit for treatment

Full description

In this study was assessed the associations among most frequently mutated genes and with clinicopathological features, as well as the prognostic significance of the presence of mutations in the top mutated and DNA Damage response (DDR) mutated genes in terms of Overall Survival (OS). Moreover, overall tumor-infiltrating lymphocytes (TILs) density was measured, analyzed immunohistochemically the expression of PD-L1, the four MMR proteins (MLH1, MSH2, MSH6 and PMS2) and tumor or stromal CD8+ cytotoxic T lymphocyte infiltrates and assessed their association with each other, top mutated genes and available clinicopathological parameters together with their role in prognosis.

Enrollment: 66 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Urothelial carcinoma located in bladder
• Patients treated with platinum regimens at the neoadjuvant . adjuvant setting
• Written informed consent for the use of biological material

Exclusion criteria